Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy

Margolick, 1995, Failure of T‐cell homeostasis preceding AIDS in HIV‐1 infection. The multicenter AIDS cohort study, Nat Med, 1, 674, 10.1038/nm0795-674 Battegay, 2006, Immunological recovery and antiretroviral therapy in HIV‐1 infection, Lancet Infect Dis, 6, 280, 10.1016/S1473-3099(06)70463-7 Kaufmann, 2003, CD4 T‐lymphocyte recovery in individuals with advanced HIV‐1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV cohort study, Arch Intern Med, 163, 2187, 10.1001/archinte.163.18.2187 Lewden, 2007, HIV‐infected adults with a CD4 cell count greater than 500 cells/mm3 on long‐term combination antiretroviral therapy reach same mortality rates as the general population, J Acquir Immune Defic Syndr, 46, 72, 10.1097/QAI.0b013e318134257a Mocroft, 2007, Normalization of CD4 counts in patients with HIV‐1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study, Lancet, 370, 407, 10.1016/S0140-6736(07)60948-9 Moore, 2007, CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression, Clin Infect Dis, 44, 441, 10.1086/510746 Byakwaga, 2009, Evolution of CD4+ T‐cell count in HIV‐1‐infected adults receiving antiretroviral therapy with sustained long‐term virological suppression, AIDS Res Hum Retroviruses, 25, 756, 10.1089/aid.2008.0149 Torti, 2011, Long‐term CD4+ T‐cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non‐NRTI or only NRTI, BMC Infect Dis, 11, 23, 10.1186/1471-2334-11-23 Giordano, 2003, Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?, Clin Infect Dis, 37, 433, 10.1086/376638 Gras, 2007, CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater, J Acquir Immune Defic Syndr, 45, 183, 10.1097/QAI.0b013e31804d685b García, 2004, Long‐term CD4+ T‐cell response to highly active antiretroviral therapy according to baseline CD4+ T‐cell count, J Acquir Immune Defic Syndr, 36, 702, 10.1097/00126334-200406010-00007 Deeks, 2004, Immune activation set point during early HIV infection predicts subsequent CD4+ T‐cell changes independent of viral load, Blood, 104, 942, 10.1182/blood-2003-09-3333 Kuller, 2008, Inflammatory and coagulation biomarkers and mortality in patients with HIV infection, PLoS Med, 5, e203, 10.1371/journal.pmed.0050203 Phillips, 2008, The role of HIV in serious diseases other than AIDS, AIDS, 22, 2409, 10.1097/QAD.0b013e3283174636 Castagna, 2010, Predicting the magnitude of short‐term CD4+ T‐cell recovery in HIV‐infected patients during first‐line antiretroviral therapy, Antivir Ther, 15, 165, 10.3851/IMP1513 Guiguet, 2009, CD4+ T‐cell percentage is an independent predictor of clinical progression in AIDS‐free antiretroviral‐naive patients with CD4+ T‐cell counts >200 cells/mm3, Antivir Ther, 14, 451, 10.1177/135965350901400311 Clifford, 2009, Hodgkin lymphoma in the Swiss HIV cohort study, Blood, 113, 5737, 10.1182/blood-2009-02-204172 Syrjälä, 1991, Low CD4/CD8 T lymphocyte ratio in acute myocardial infarction, Clin Exp Immunol, 83, 326, 10.1111/j.1365-2249.1991.tb05636.x Lang, 2010, Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus‐infected patients: a case‐control study nested within the French Hospital Database on HIV ANRS cohort CO4, Arch Intern Med, 170, 1228, 10.1001/archinternmed.2010.197 Andersen, 1982, Cox’s regression model for counting processes, a large sample study, Ann Stat, 10, 1100, 10.1214/aos/1176345976 Therneau, 2000 Panel on Antiretroviral Guidelines for Adults and Adolescents, 2011, Guidelines for the use of antiretroviral agents in HIV‐1‐infected adults and adolescents, Department of Health and Human Services, 1 Hastie, 2009 Shaffer, 1995, Multiple hypothesis testing, Annual Rev Psychol, 46, 561, 10.1146/annurev.ps.46.020195.003021 R Development Core Team, 2009 Tarwater, 2001, Increase and plateau of CD4+ T‐cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy, J Acquir Immune Defic Syndr, 27, 168, 10.1097/00126334-200106010-00012 Valdez, 2002, Limited immune restoration after 3 years’ suppression of HIV‐1 replication in patients with moderately advanced disease, AIDS, 16, 1859, 10.1097/00002030-200209270-00002 2008, Response to combination antiretroviral therapy: variation by age, AIDS, 22, 1463, 10.1097/QAD.0b013e3282f88d02 Bennett, 2002, Baseline predictors of CD4 T‐lymphocyte recovery with combination antiretroviral therapy, J Acquir Immune Defic Syndr, 31, 20, 10.1097/00126334-200209010-00003 Gandhi, 2006, Effect of baseline‐ and treatment‐related factors on immunologic recovery after initiation of antiretroviral therapy in HIV‐1‐positive subjects: results from ACTG 384, J Acquir Immune Defic Syndr, 42, 426, 10.1097/01.qai.0000226789.51992.3f Bosch, 2007, Pretreatment factors associated with 3‐year (144‐week) virologic and immunologic responses to potent antiretroviral therapy, J Acquir Immune Defic Syndr, 44, 268, 10.1097/QAI.0b013e31802c7e20 Dronda, 2002, Long‐term outcomes among antiretroviral‐naive human immunodeficiency virus‐infected patients with small increases in CD4+ cell counts after successful virologic suppression, Clin Infect Dis, 35, 1005, 10.1086/342695 Barreiro, 2002, Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non nucleosides, AIDS, 16, 245, 10.1097/00002030-200201250-00014 Daar, 2011, Atazanavir plus ritonavir or efavirenz as part of a 3‐drug regimen for initial treatment of HIV‐1, Ann Intern Med, 154, 445, 10.7326/0003-4819-154-7-201104050-00316 Sierra‐Madero, 2011, Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment‐naive subjects with CD4+<200 cell/mm3 in Mexico, J Acquir Immune Defic Syndr, 53, 582, 10.1097/QAI.0b013e3181cae4a1 Echeverría, 2010, Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral‐naïve patients: a 48‐week, multicentre, randomized study (Lake Study), Antiviral Res, 85, 403, 10.1016/j.antiviral.2009.11.008 Kelley, 2009, Incomplete peripheral CD4+ cell count restoration in HIV‐infected patients receiving long‐term antiretroviral treatment, Clin Infect Dis, 48, 787, 10.1086/597093